Cargando…

Long-term sexual functioning in germ-cell tumor survivors

BACKGROUND: Survivors of germ-cell tumors (GCT) may suffer from long-term adverse consequences. Our study was conducted to assess a long-term sexual functioning in GCT survivors. METHODS: GCT survivors (N = 170) from the National Cancer Institute in Slovakia completed a Sexual Function Questionnaire...

Descripción completa

Detalles Bibliográficos
Autores principales: Chovanec, M., Vasilkova, L., Petrikova, L., Obertova, J., Palacka, P., Rejlekova, K., Sycova-Mila, Z., Kalavska, K., Svetlovska, D., Mladosievicova, B., Mardiak, J., Mego, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439516/
https://www.ncbi.nlm.nih.gov/pubmed/32819309
http://dx.doi.org/10.1186/s12885-020-07301-6
_version_ 1783573000092647424
author Chovanec, M.
Vasilkova, L.
Petrikova, L.
Obertova, J.
Palacka, P.
Rejlekova, K.
Sycova-Mila, Z.
Kalavska, K.
Svetlovska, D.
Mladosievicova, B.
Mardiak, J.
Mego, M.
author_facet Chovanec, M.
Vasilkova, L.
Petrikova, L.
Obertova, J.
Palacka, P.
Rejlekova, K.
Sycova-Mila, Z.
Kalavska, K.
Svetlovska, D.
Mladosievicova, B.
Mardiak, J.
Mego, M.
author_sort Chovanec, M.
collection PubMed
description BACKGROUND: Survivors of germ-cell tumors (GCT) may suffer from long-term adverse consequences. Our study was conducted to assess a long-term sexual functioning in GCT survivors. METHODS: GCT survivors (N = 170) from the National Cancer Institute in Slovakia completed a Sexual Function Questionnaire that was modified from PROMIS Sexual Function and Satisfaction Questionnaire 9-year median follow up (range 5–32) as a primary exploratory aim. Study groups consisted of 17 survivors (10%) who had active surveillance (AS, controls), and 153 (90%) survivors who received treatment beyond orchiectomy (Tx), including cisplatin-based chemotherapy (CT, N = 132; 78%), radiotherapy to the retroperitoneal lymph nodes (RT, N = 12; 7%) or both (CTRT, N = 9; 5%). RESULTS: In univariate analysis, treatment of any type resulted in difficulty to maintain erection during sexual intercourse compared to patients treated with AS (P = 0.04). Survivors who received CTRT had lower ability to achieve orgasm during sexual activities (P = 0.04) and they reported disappointment with their overall quality of sex life (P = 0.002). The number of attempts to initiate sexual intercourse did not differ. Sexual relationships caused none or mild anxiety and the desire to be sexually active was higher after CTRT (P = 0.05). Multivariable analysis confirmed that orgasmic dysfunction after ≥400 mg/m(2) of cisplatin and issues in maintaining erection after Tx were independent of retroperitoneal lymph-node dissection (P = 0.03 and P = 0.04, respectively). Survivors were disappointed with the quality of sex life and had stronger desire to be sexually active independent of age, (P = 0.01 and P = 0.05, respectively). CONCLUSIONS: This study identified an impairment in sexual function may represent an issue for long-term GCT survivors. Treatment with chemotherapy plus radiotherapy were associated with disappointment and stronger sexual desire, while a higher cumulative dose of cisplatin may be responsible for orgasmic dysfunction.
format Online
Article
Text
id pubmed-7439516
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74395162020-08-24 Long-term sexual functioning in germ-cell tumor survivors Chovanec, M. Vasilkova, L. Petrikova, L. Obertova, J. Palacka, P. Rejlekova, K. Sycova-Mila, Z. Kalavska, K. Svetlovska, D. Mladosievicova, B. Mardiak, J. Mego, M. BMC Cancer Research Article BACKGROUND: Survivors of germ-cell tumors (GCT) may suffer from long-term adverse consequences. Our study was conducted to assess a long-term sexual functioning in GCT survivors. METHODS: GCT survivors (N = 170) from the National Cancer Institute in Slovakia completed a Sexual Function Questionnaire that was modified from PROMIS Sexual Function and Satisfaction Questionnaire 9-year median follow up (range 5–32) as a primary exploratory aim. Study groups consisted of 17 survivors (10%) who had active surveillance (AS, controls), and 153 (90%) survivors who received treatment beyond orchiectomy (Tx), including cisplatin-based chemotherapy (CT, N = 132; 78%), radiotherapy to the retroperitoneal lymph nodes (RT, N = 12; 7%) or both (CTRT, N = 9; 5%). RESULTS: In univariate analysis, treatment of any type resulted in difficulty to maintain erection during sexual intercourse compared to patients treated with AS (P = 0.04). Survivors who received CTRT had lower ability to achieve orgasm during sexual activities (P = 0.04) and they reported disappointment with their overall quality of sex life (P = 0.002). The number of attempts to initiate sexual intercourse did not differ. Sexual relationships caused none or mild anxiety and the desire to be sexually active was higher after CTRT (P = 0.05). Multivariable analysis confirmed that orgasmic dysfunction after ≥400 mg/m(2) of cisplatin and issues in maintaining erection after Tx were independent of retroperitoneal lymph-node dissection (P = 0.03 and P = 0.04, respectively). Survivors were disappointed with the quality of sex life and had stronger desire to be sexually active independent of age, (P = 0.01 and P = 0.05, respectively). CONCLUSIONS: This study identified an impairment in sexual function may represent an issue for long-term GCT survivors. Treatment with chemotherapy plus radiotherapy were associated with disappointment and stronger sexual desire, while a higher cumulative dose of cisplatin may be responsible for orgasmic dysfunction. BioMed Central 2020-08-20 /pmc/articles/PMC7439516/ /pubmed/32819309 http://dx.doi.org/10.1186/s12885-020-07301-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Chovanec, M.
Vasilkova, L.
Petrikova, L.
Obertova, J.
Palacka, P.
Rejlekova, K.
Sycova-Mila, Z.
Kalavska, K.
Svetlovska, D.
Mladosievicova, B.
Mardiak, J.
Mego, M.
Long-term sexual functioning in germ-cell tumor survivors
title Long-term sexual functioning in germ-cell tumor survivors
title_full Long-term sexual functioning in germ-cell tumor survivors
title_fullStr Long-term sexual functioning in germ-cell tumor survivors
title_full_unstemmed Long-term sexual functioning in germ-cell tumor survivors
title_short Long-term sexual functioning in germ-cell tumor survivors
title_sort long-term sexual functioning in germ-cell tumor survivors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439516/
https://www.ncbi.nlm.nih.gov/pubmed/32819309
http://dx.doi.org/10.1186/s12885-020-07301-6
work_keys_str_mv AT chovanecm longtermsexualfunctioningingermcelltumorsurvivors
AT vasilkoval longtermsexualfunctioningingermcelltumorsurvivors
AT petrikoval longtermsexualfunctioningingermcelltumorsurvivors
AT obertovaj longtermsexualfunctioningingermcelltumorsurvivors
AT palackap longtermsexualfunctioningingermcelltumorsurvivors
AT rejlekovak longtermsexualfunctioningingermcelltumorsurvivors
AT sycovamilaz longtermsexualfunctioningingermcelltumorsurvivors
AT kalavskak longtermsexualfunctioningingermcelltumorsurvivors
AT svetlovskad longtermsexualfunctioningingermcelltumorsurvivors
AT mladosievicovab longtermsexualfunctioningingermcelltumorsurvivors
AT mardiakj longtermsexualfunctioningingermcelltumorsurvivors
AT megom longtermsexualfunctioningingermcelltumorsurvivors